ACCC COVID-19 Resource Center & Listserv
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Minnesota's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1992
Meetings & Education
Financial Advocacy & Patient Assistance
MSCO Educational Award
MSCO Advocacy Support
Patient Advocacy Organizations
State & Federal Resources
Find A Clinical Trial
Off-Label Use Literature
National Professional Organizations
MSCO Corporate Members
Become a Corporate Member
Industry News Archive
FDA Approves Selinexor for Multiple Myeloma
On July 3, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selinexor (Xpovio, Karyopharm Therapeutics) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
As a condition of accelerated approval, further clinical trials may be required to verify and describe selinexor’s benefit. FDA granted this application fast track designation and orphan drug designation.
Read FDA announcement
Tweets by OSSatACCC